Tadocizumab

Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system. It binds to integrin αIIbβ3, a fibrinogen and fibronectin receptor found on platelets. The drug is designed for the treatment of patients undergoing percutaneous coronary interventions. It was developed by Yamanōchi Pharma America, Inc.